Join our email list to stay up to date on the latest Amyloidosis news.
Yesterday was a big milestone for the ATTR amyloidosis community.
Pfizer announced the results from their phase III ATTR-ACT study of tafamidis for patients with cardiac ATTR amyloidosis. The results demonstrated a statistically significant reduction in the numbers of deaths and cardiac-related hospitalizations compared to a placebo during the study period.
To date there are no approved therapies for cardiac ATTR amyloidosis, and this news is an important milestone for patients and their families. We look forward to Pfizer sharing more detailed results in the upcoming months and the FDA’s review of this data. We are grateful to Pfizer for their ongoing commitment to ATTR amyloidosis.
You can read the full press release here.